Kodiak Sciences Inc. (NASDAQ:KOD) Forecasted to Earn Q1 2022 Earnings of ($0.80) Per Share

Kodiak Sciences Inc. (NASDAQ:KODGet Rating) – Equities research analysts at Truist Financial issued their Q1 2022 earnings per share estimates for shares of Kodiak Sciences in a report released on Tuesday, April 12th. Truist Financial analyst R. Karnauskas anticipates that the company will earn ($0.80) per share for the quarter. Truist Financial also issued estimates for Kodiak Sciences’ Q2 2022 earnings at ($0.81) EPS, Q3 2022 earnings at ($0.83) EPS and Q4 2022 earnings at ($0.85) EPS.

Several other research analysts have also recently weighed in on KOD. Morgan Stanley decreased their target price on Kodiak Sciences from $17.00 to $12.00 and set an “equal weight” rating for the company in a research note on Tuesday. Barclays decreased their target price on Kodiak Sciences from $81.00 to $50.00 and set an “underweight” rating for the company in a research note on Monday, February 7th. Citigroup decreased their target price on Kodiak Sciences from $70.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 24th. Roth Capital decreased their target price on Kodiak Sciences from $149.00 to $75.00 in a research note on Monday, February 28th. Finally, Chardan Capital decreased their price target on Kodiak Sciences from $82.50 to $19.00 in a research report on Tuesday, March 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $45.33.

Shares of KOD stock opened at $7.20 on Thursday. The stock has a 50-day simple moving average of $20.90 and a 200 day simple moving average of $66.85. Kodiak Sciences has a fifty-two week low of $6.81 and a fifty-two week high of $26.39.

In other news, insider Jason Ehrlich sold 6,950 shares of the firm’s stock in a transaction dated Thursday, January 20th. The stock was sold at an average price of $64.39, for a total transaction of $447,510.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 5,800 shares of the business’s stock in a transaction dated Tuesday, February 15th. The shares were purchased at an average cost of $54.16 per share, with a total value of $314,128.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 1,093,818 shares of company stock valued at $60,465,648. Company insiders own 39.70% of the company’s stock.

Hedge funds have recently modified their holdings of the stock. US Bancorp DE raised its stake in shares of Kodiak Sciences by 53.5% in the 3rd quarter. US Bancorp DE now owns 508 shares of the company’s stock valued at $49,000 after acquiring an additional 177 shares in the last quarter. Lindbrook Capital LLC grew its holdings in shares of Kodiak Sciences by 2,160.0% during the 4th quarter. Lindbrook Capital LLC now owns 565 shares of the company’s stock worth $48,000 after purchasing an additional 540 shares in the last quarter. Exane Derivatives grew its holdings in shares of Kodiak Sciences by 8,472.7% during the 4th quarter. Exane Derivatives now owns 943 shares of the company’s stock worth $80,000 after purchasing an additional 932 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $124,000. Finally, Capital Impact Advisors LLC acquired a new stake in shares of Kodiak Sciences during the 4th quarter worth approximately $148,000. 87.85% of the stock is currently owned by institutional investors and hedge funds.

About Kodiak Sciences (Get Rating)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Further Reading

Earnings History and Estimates for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.